)
)
)
Bisc Therapeutics, Inc.
Bisc Therapeutics is developing first-in-class small-molecule inhibitors of Bax to halt age-related tissue degeneration, with an initial focus on ocular disease. Our lead program is a sustained-release Bax inhibitor designed to prevent retinal cell loss in Geographic Atrophy (GA)—the advanced form of dry AMD and a leading cause of irreversible vision loss affecting 8 million people worldwide. Bisc is currently raising a $7M Seed round to advance this development-candidate–stage program to IND submission and Phase 1 readiness within 18 months.
Address
ClevelandUnited States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)